0.23
price up icon3.00%   0.0067
after-market 시간 외 거래: .23
loading

Scisparc Ltd 주식(SPRC)의 최신 뉴스

pulisher
Nov 04, 2024

SciSparc Ltd. Reports Changes in Financial Position - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com

Nov 04, 2024
pulisher
Oct 23, 2024

SciSparc Ltd. Gains Shareholder Approval for Proposals - TipRanks

Oct 23, 2024
pulisher
Oct 22, 2024

SciSparc Ltd. Reschedules Annual General Meeting - TipRanks

Oct 22, 2024
pulisher
Oct 16, 2024

Examining SPRC’s book value per share for the latest quarter - US Post News

Oct 16, 2024
pulisher
Oct 16, 2024

Financial Metrics Unveiled: SciSparc Ltd (SPRC)’s Key Ratios in the Spotlight - The Dwinnex

Oct 16, 2024
pulisher
Oct 09, 2024

SPRC Stock Hits 52-Week Low at $0.21 Amid Market Challenges - Investing.com

Oct 09, 2024
pulisher
Oct 08, 2024

SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN

Oct 08, 2024
pulisher
Oct 01, 2024

SciSparc stock plunges to 52-week low, hits $0.23 - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome - 420 Intel

Oct 01, 2024
pulisher
Oct 01, 2024

SciSparc receives FDA approval for trial for Tourette syndrome therapy - Clinical Trials Arena

Oct 01, 2024
pulisher
Oct 01, 2024

SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN

Oct 01, 2024
pulisher
Sep 30, 2024

FDA greenlights SciSparc's Phase IIb Tourette Syndrome study By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Pharmaceutical FDA Next Phase Cannabinoid For TouretteSciSparc (NASDAQ:SPRC) - Benzinga

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc secures FDA approval to launch Phase IIB trial for TS treatment - TipRanks

Sep 30, 2024
pulisher
Sep 30, 2024

FDA greenlights SciSparc's Phase IIb Tourette Syndrome study - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its - GlobeNewswire

Sep 30, 2024
pulisher
Sep 30, 2024

Financial Metrics Check: SciSparc Ltd (SPRC)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - StockTitan

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Ltd (SPRC) stock: A year of ups and downs - US Post News

Sep 30, 2024
pulisher
Sep 29, 2024

SciSparc signs LOI to sell entire ownership in MitoCareX - MSN

Sep 29, 2024
pulisher
Sep 27, 2024

SciSparc Ltd. Proposes Reverse Stock Split - TipRanks

Sep 27, 2024
pulisher
Sep 26, 2024

SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire

Sep 26, 2024
pulisher
Sep 25, 2024

Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Smartgroup Announces Major Shareholding Changes - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

Science Group PLC Executes Share Buyback - TipRanks

Sep 25, 2024
pulisher
Sep 24, 2024

Site Group Plans Massive New Share Issue - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle

Sep 24, 2024
pulisher
Sep 24, 2024

SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts

Sep 24, 2024
pulisher
Sep 24, 2024

Clearmind, SciSparc slide amid weight-loss study results - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter

Sep 24, 2024
pulisher
Sep 24, 2024

UBS Cuts Stake in Spirent Communications - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree maintains expectations amid tough market conditions. - Research the market

Sep 24, 2024
pulisher
Sep 24, 2024

UK recruiter SThree falls on lower Q3 net fee - XM

Sep 24, 2024
pulisher
Sep 24, 2024

SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK

Sep 24, 2024
pulisher
Sep 24, 2024

Science Group PLC Announces Share Buyback - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree plc Navigates Market Headwinds in Q3 - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree Net Fees Fall Amid Challenging Environment - MarketWatch

Sep 24, 2024
pulisher
Sep 24, 2024

Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.

Sep 24, 2024
pulisher
Sep 23, 2024

100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Market Watch: SciSparc Ltd (SPRC)’s Noteworthy Drop, Closing at 0.26 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Barclays Ups Stake in Spirent Communications - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

FDA greenlights SciSparc's phase IIb trial for Tourette Syndrome - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Are SciSparc Ltd’shares a good deal? - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

SciSparc Advances Tourette Syndrome Drug Trial - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Sep 23, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):